Editor's letter

Issue 156 • July 2025

Don’t miss out – sign up to our free industry-leading magazine and newsletters

Cover image: text. Credit: ?

Welcome to the latest issue of Pharmaceutical Technology Focus magazine

The uptake of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in the US for weight loss has been profound. However, compounded GLP-1's, generic versions of the drugs, have upended pricing models for market leader Novo Nordisk's Wegovy (semaglutide) and Eli Lilly's Mounjaro (tirzepatide).

Our cover feature examines the effect the FDA's order that compounders stop producing versions of semaglutide and tirzepatide as both drugs are no longer in short supply is liable to have on the market.

Also in this issue, we look at whether pharma tariffs can ''Make America Manufacture Again' and how companies are navigating the psychedelic drug-trial  field. And don’t miss our roundup of the biggest news from this year's American Society of Clinical Oncology meeting.

All this and the latest pharma industry news, comment, and analysis from GlobalData.

Ross Law, deputy editor

Go to article: Home | Why can’t the US figure out weight loss drug prices?Go to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: Syngene Company InsightGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Precision Health Technologies Accelerator Company InsightGo to article: In DepthGo to article: Why can’t the US figure out weight loss drug prices?Go to article: Psychedelic drug developers redesign trials to avoid Lykos faux pasGo to article: Can pharma tariffs “Make America Manufacture Again”?Go to article: Policy changes and digital strategies guide oncology researchGo to article: The European Market Access Lag: 2021–2024Go to article: Vutrisiran marks first silencer approved for ATTR-CMGo to article: ASCO 2025: Key highlightsGo to article: SCHOTT Pharma Company InsightGo to article: ListingsGo to article: EventsGo to article: Excellence AwardsGo to article: Excellence Awards 2025: NovotechGo to article: Buyer's GuidesGo to article: Next issue